Testing played a critical role in addressing the COVID-19 threat. The battle was fought on multiple fronts, from physicians’ offices and urgent care clinics to hospitals and molecular labs, and from emergency departments to hotspots where help was needed most.

We worked across our company and in partnership with others to support communities worldwide with resources and technologies to fight that evolving threat. We aided in the development of new tests so people could receive the critical results they needed and ensured continued access to critical biological samples for diagnostics development without disruption.

Fast, accurate detection and monitoring for health issues that arose as part of COVID-19 disease management were critical. Our sample availability across immunoassay, chemistry, hematology, hemostasis, molecular, and urinalysis helped support the essential role of laboratory diagnostics. We continued to support the in-vitro diagnostics industry by expanding our infectious disease sample collection capabilities to address the COVID-19 pandemic.

New York Biologics provided PCR transport media, as well as serology samples (positives and negatives) with date of symptom onset.

While the acute phase of the pandemic has passed, we remain committed to contributing to scientific research to help control COVID-19 wherever it may still be present. We were proud to assist the IVD industry in the fight against SARS-CoV-2.